Third Rock Ventures III, L.P.

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Kevin Gillis, Chief Operating Officer of TRV GP III, LLC, general partner of Third Rock Ventures GP III, L.P., general partner of Third Rock Ventures III, L.P.
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Third Rock Ventures III, L.P.

Form 4 holding 10%+ Owner

Revolution Medicines, Inc.

Security class
Common Stock
Shares / value
5,104,130
Estimated value
$137,811,510
Report date
08 Jun 2022
Price
$27.00
Ownership
Direct
Form 4 holding 10%+ Owner

PLIANT THERAPEUTICS, INC.

Security class
Common Stock
Shares / value
2,132,867
Estimated value
$36,749,298
Report date
29 Nov 2022
Price
$17.23
Ownership
Indirect
Form 4 holding 10%+ Owner

Nurix Therapeutics, Inc.

Security class
Common Stock
Shares / value
3,422,549
Estimated value
$34,236,100
Report date
06 May 2021
Price
$10.00
Ownership
Direct
Form 4 holding 10%+ Owner

PLIANT THERAPEUTICS, INC.

Security class
Common Stock
Shares / value
1,839,160
Estimated value
$31,688,727
Report date
29 Nov 2022
Price
$17.23
Ownership
Direct
Form 4 holding 10%+ Owner

Voyager Therapeutics, Inc.

Security class
Common Stock
Shares / value
3,185,291
Estimated value
$22,774,831
Report date
02 Feb 2023
Price
$7.15
Ownership
Direct
Form 4 holding 10%+ Owner

Fulcrum Therapeutics, Inc.

Security class
Common Stock
Shares / value
2,343,154
Estimated value
$7,755,840
Report date
13 Dec 2022
Price
$3.31
Ownership
Indirect
Form 4 holding 10%+ Owner

Fulcrum Therapeutics, Inc.

Security class
Common Stock
Shares / value
1,962,202
Estimated value
$6,494,889
Report date
13 Dec 2022
Price
$3.31
Ownership
Direct
Form 4 holding 10%+ Owner

Jounce Therapeutics, Inc.

Security class
Common Stock
Shares / value
1,148,780
Estimated value
$2,125,243
Report date
12 Nov 2021
Price
$1.85
Ownership
Direct
Form 4 holding 10%+ Owner

Nurix Therapeutics, Inc.

Security class
Common Stock
Shares / value
86,799
Estimated value
$868,259
Report date
06 May 2021
Price
$10.00
Ownership
Indirect
Form 4 holding 10%+ Owner

Jounce Therapeutics, Inc.

Security class
Common Stock
Shares / value
283,858
Estimated value
$525,137
Report date
12 Nov 2021
Price
$1.85
Ownership
Indirect

Insider Reports Filed by Third Rock Ventures III, L.P.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .